Presentation is loading. Please wait.

Presentation is loading. Please wait.

Establishment of transcriptional class distinction in melanocytes.

Published byAudra Manning Modified over 5 years ago

Similar presentations

Presentation on theme: "Establishment of transcriptional class distinction in melanocytes."— Presentation transcript:

1 Establishment of transcriptional class distinction in melanocytes.
Establishment of transcriptional class distinction in melanocytes. A, effects of aberrant MAPK pathway activation on melanocyte whole-genome expression profiles. B, effects of aberrant MAPK pathway activation on markers of the MITF-high and NF-κB–high classes; E, VTX11E (ERKi); P, PLX4720 (RAFi); A, AZD6244 (MEKi), all overnight at 2 μmol/L. C, effects of chronic BRAFV600E expression on markers of the MITF-high and NF-κB–high classes. Experiments were performed in TICVA medium (+) or Ham's F10 (−) as indicated. D, effect of MITF overexpression on MAPK pathway–induced expression changes. n.s., nonspecific band. E, relationship between MITF expression levels and MITF amplification in melanoma cell lines. David J. Konieczkowski et al. Cancer Discovery 2014;4: ©2014 by American Association for Cancer Research

Download ppt "Establishment of transcriptional class distinction in melanocytes."

Similar presentations

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.
Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.

Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.
miR-133a positively regulated p53/p21 pathway.

miR-133a positively regulated p53/p21 pathway.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.
Fig. 6. Pathway analysis of CMLD

Fig. 6. Pathway analysis of CMLD
PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.
Diverse abnormalities manifest in RNA

Diverse abnormalities manifest in RNA
MITF upregulation leads to Hsp90i resistance

MITF upregulation leads to Hsp90i resistance
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.

Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.
A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.
Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.
AMPK induces VEGF-A production by upregulating ERK signaling.

AMPK induces VEGF-A production by upregulating ERK signaling.

Similar presentations

Ads by Google